Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
| Autor: | Jeffrey R. Bishop, Stuart A. Scott, SG Leckband, Rebecca L. Graham, Julia C. Stingl, J. S. Leeder, DL Chiulli, Andrea Gaedigk, Daniel J. Müller, Todd C. Skaar, Kelly E. Caudle, Katrin Sangkuhl, JK Hicks, Yuan Ji, Adrián LLerena, Teri E. Klein |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty Genotype Fluvoxamine Citalopram Biology Pharmacology Risk Assessment behavioral disciplines and activities Risk Factors Internal medicine mental disorders medicine Humans Escitalopram Drug Dosage Calculations Pharmacology (medical) Dosing Serotonin Uptake Inhibitors Biotransformation Sertraline Polymorphism Genetic Paroxetine Cytochrome P-450 CYP2C19 Phenotype Cytochrome P-450 CYP2D6 Pharmacogenetics CPIC Guidelines Patient Safety Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Clinical Pharmacology & Therapeutics. 98:127-134 |
| ISSN: | 0009-9236 |
| DOI: | 10.1002/cpt.147 |
| Popis: | Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text